There's stories from a few ladies (reddit) who moved from Nuvaring (short term) to Annovera (long term) with great results. Some of the feedback really does give you hope with the Annovera purchase.
(larger but more flexible, annual rather than short-term, less side effects)
Not too sure how Nuvaring type fits into the portfolio. From the outside appears old generation v new. Maybe from someone using Nuvaring looking for a cheaper alternative... argh generics
Hard to see Halloette really having an impact on the bottom line or Mayne spending much $ pushing it. Just would be following through on a process started ~3 years ago - and for Mithra, unlocking that final $1.6m EUR
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)